Who should get a liver graft?

Journal of Hepatology

Volumn 50, Issue 4, 2009, Pages 664-673

  Freeman, Richard B ^a   Jamieson, Neville ^b   Schaubel, Douglas E ^c   Porte, Robert J ^d   Villamil, Federico G ^e  

^a TUFTS MEDICAL CENTER   (United States)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL;

CANCER STAGING; CHEMOEMBOLIZATION; HEALTH CARE SYSTEM; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FAILURE; LIVER GRAFT; LIVER TRANSPLANTATION; MEDICAL DECISION MAKING; MORTALITY; ORGAN DONOR; PATIENT CODING; PATIENT SELECTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SURVIVAL; UNITED KINGDOM; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; GREAT BRITAIN; HEALTH CARE RATIONING; HUMANS; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PATIENT DROPOUTS; PATIENT SELECTION; RESOURCE ALLOCATION; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVORS; TISSUE AND ORGAN PROCUREMENT; TREATMENT FAILURE;

EID: 61749088968     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.01.013     Document Type: Review

References (60)

1. Neuberger J., and James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. Lancet 354 (1999) 1636-1639
2. Neuberger J., Gimson A., Davies M., Akyol M., O'Grady J., Burroughs A., et al. Liver Advisory Group; UK blood and transplant. Selection of patients for liver transplantation and allocation of donated livers in the UK. Gut 57 (2008) 252-257
3. Organ Donation Taskforce. Organs for transplants. A report from the Organ Donation Taskforce. Department of Health, Crown Publications; 2008.
4. Freeman R.B. MELD: the holy grail of organ allocation?. J Hepatol 42 (2005) 16-20
5. Freeman Jr. R.B. The model for end-stage liver disease comes of age. Clin Liver Dis 11 (2007) 249-263
6. Freeman R.B., Harper A., and Edwards E.B. Excellent liver transplant survival rates under the MELD/PELD system. Transpl Proc 37 (2005) 585-588
7. Volk M.L., Lok A.S., Pelletier S.J., Ubel P.A., and Hayward R.A. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology 135 (2008) 1568-1574
8. Merion R.M., Schaubel D.E., Dykstra D.M., Freeman R.B., Port F.K., and Wolfe R.A. The survival benefit of liver transplantation. Am J Transpl 5 (2005) 307-313
9. Freeman Jr. R.B. Utility is not just posttransplant outcome!. Am J Transpl 6 (2006) 2817
10. Schaubel DE, Wolfe RA, Sima CS, Merion RM. Estimating the effect of a time-dependent treatment by levels of an internal time-dependent covariate. J Am Stat Assoc, in press.
11. Schaubel D.E., Sima C.S., Goodrich N.P., Feng S., and Merion R.M. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transpl 8 (2008) 419-425
12. Berg C.L., Gillespie B.W., Merion R.M., Brown Jr. R.S., Abecassis M.M., Trotter J.F., et al. A2ALL Study Group. Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology 133 (2007) 1806-1813
13. Merion R.M., Ashby V.B., Wolfe R.A., Distant D.A., Hulbert-Shearon T.E., Metzger R.A., et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. J Am Med Assoc 294 (2005) 2726-2733
14. Egan T.M., Murray S., Bustami R.T., Shearon T.H., McCullough K.P., Edwards L.B., et al. Development of the new lung allocation system in the United States. Am J Transpl 6 (2006) 1212-1227
15. Wolfe R.A., McCullough K.P., Schaubel D.E., Kalbfleisch J.D., Murray S., Stegall M.D., et al. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transpl 8 (2008) 997-1011
16. Schaubel DE, Guidinger MK, Biggins SW, Kalbfleisch JD, Pomfret EA, Sharma P, et al. Survival benefit-based deceased-donor liver allocation. Am J Transpl, in press.
17. Malinchoc M., Kamath P.S., Gordon F.D., Peine C.J., Rank J., and ter Borg P.C. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 (2000) 864-871
18. Kamath P.S., Wiesner R.H., Malinchoc M., Kremers W., Therneau T.M., Kosberg C.L., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001) 464-470
19. Wiesner R.H., McDiarmid S.V., Kamath P.S., Edwards E.B., Malinchoc M., Kremers W.K., et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 7 (2001) 567-580
20. Sharma P., Schaubel D.E., Sima C.S., Merion R.M., and Lok A.S.F. Re-weighting the model for end-stage liver disease score components. Gastroenterology 135 (2008) 1575-1581
21. Biggins S.W., Kim W.R., Terrault N.A., Saab S., Balan V., Schiano T., et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130 (2006) 1652-1660
22. Kim W.R., Biggins S.W., Kremers W.K., Wiesner R.H., Kamath P.S., Benson J.T., et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 359 (2008) 1018-1026
23. Burra P., and Porte R.J. Should donors and recipients be matched in liver transplantation?. J Hepatol 45 (2006) 488-494
24. Müllhaupt B., Dimitroulis D., Gerlach J.T., and Clavien P.A. Hot topics in liver transplantation: organ allocation - extended criteria donor - living donor liver transplantation. J Hepatol 48 (2008) S58-S67
25. Mittler J., Pascher A., Neuhaus P., and Pratschke J. The utility of extended criteria donor organs in severely ill liver transplant recipients. Transplantation 86 (2008) 895-896
26. Cameron A.M., Ghobrial R.M., Yersiz H., Farmer D.G., Lipshutz G.S., Gordon S.A., et al. Optimal utilization of donor grafts with extended criteria. A single-center experience in over 1000 liver transplants. Ann Surg 243 (2006) 748-755
27. Cameron A., and Busuttil R. AASLD/ILTS transplant course: is there an extended donor suitable for everyone?. Liver Transpl 11 Suppl. 1 (2005) S2-S5
28. Feng S., Goodrich N.P., Bragg-Gresham J.L., Dykstra D.M., Punch J.D., DebRoy M.A., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transpl 6 (2006) 783-790
29. Durand F., Renz J.F., Alkofer B., Burra P., Clavien P.A., Porte R.J., et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 14 (2008) 1694-1707
30. Attia M., Silva M.A., and Mirza D.F. The marginal liver donor - an update. Transpl Int 21 (2008) 713
31. Hashimoto K., and Miller C. The use of marginal grafts in liver transplantation. J Hepatobiliary Pancreat Surg 15 (2008) 92-101
32. Briceno J., Padillo J., Rufián S., Solórzano G., and Pera C. Assignment of steatotic livers by the Mayo model for end-stage liver disease. Transpl Int 18 (2005) 577-583
33. Amin M.G., Wolf M.P., TenBrook J.A., Freeman Jr. R.B., Cheng S.J., Pratt D.S., et al. Expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl 10 (2004) 1468-1475
34. McCormack L., Petrowsky H., Jochum W., Mullhaupt B., and Clavien P.A. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 246 (2007) 940-946
35. Briceno J., Ciria R., Pleguezuelo M., de la Mata M., Muntané J., Naranjo A., et al. Impact of donor graft steatosis on overall ouycome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 15 (2009) 37-48
36. Majella Doyle M.B., Anderson C.D., Vachharajani N., Lowell J.A., Shenoy S., Lisker-Melman M., et al. Liver transplantation for hepatitis C. Effect of using older donor grafts on short- and medium-term survival. Arch Surg 143 (2008) 679-685
37. Freeman R.B., Weisner R.H., Harper A., McDairmid S.V., Lake J., Edwards E.B., et al. The new liver allocation system: moving towards evidence-based transplantation policy. Liver Transpl 8 (2002) 851-858
38. Wiesner R.H., Freeman R.B., and Mulligan D.C. Liver transplant for hepatocelluar carcinoma: the impact of the MELD allocation policy. Gastroenterology 127 5 Suppl. 1 (2004) S261-S267
39. Wiesner R., Lake J.R., Freeman R.B., and Gish R.G. Model for end stage liver disease (MELD) exception guidelines. Liver Transpl 12 Suppl. 3 (2006) S85-S87
40. Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
41. Yao F.Y., Xiao L., Bass N.M., Kerlan R., Ascher N.L., and Roberts J.P. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transpl 7 (2007) 2587-2596
42. Iwatsuki S., Dvorchik I., Marsh J.W., Madariaga J.R., Carr B., Fung J.J., et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 191 (2000) 389-394
43. Piscaglia F., Camaggi V., Ravaioli M., Grazi G.L., Zanello M., Leoni S., et al. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system. Liver Transpl 13 (2007) 857-866
44. Freeman R.B., Edwards E.B., and Harper A.M. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transpl 6 (2006) 1416-1421
45. Freeman Jr. R.B., Steffick D.E., Guidinger M.K., Farmer D.G., Berg C.L., and Merion R.M. Liver and intestine transplantation in the United States, 1997-2006. Am J Transpl 8 (2008) 958-976
46. Otto G., Herber S., Heise M., Lohse A.W., Monch C., Bittinger F., et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 12 (2006) 1260-1267
47. Yao F.Y., Hirose R., LaBerge J.M., Davern III T.J., Bass N.M., Kerlan Jr. R.K., et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11 (2005) 1505-1514
48. Ichai P., and Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl 14 (2008) S67-S79
49. Lee W.M., Squires Jr. R.H., Nyberg S.L., Doo E., and Hoofnagle J.H. Acute liver failure: summary of a workshop. Hepatology 47 (2008) 1401-1415
50. O'Grady J.G., Graeme J.M., Hayllar K.M., and Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439-445
51. Yantorno S.E., Kremers W.K., Ruf A.E., Trentadue J.J., Podesta L.G., and Villamil F.G. MELD is superior to King's College and Clichy's criteria to assess prognosis in fulminant hepatic failure. Liver Transpl 13 (2007) 822-828
52. Kremers W.K., Van Ijperen M., Kim W.R., Freeman R.B., Harper A.M., Kamath P.S., et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 39 (2004) 764-769
53. Bernuau J., Goudeau A., Poynard T., Dubois F., Lesage F., Yvonnet B., et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology 6 (1986) 648-651
54. Yantorno S.E., Kremers W.K., Ruf A.E., Trentadue J.J., Andriani O.C., Podesta L.G., et al. MELD is superior to the King's college and Clichy's criteria irrespective of the clinical variants or etiology of fulminant hepatic failure. Liver Transpl 11 (2005) C-1 (A1)
55. Katoonizadeh A., Decaestecker J., Wilmer A., Aerts R., Verslype C., Vansteenbergen W., et al. MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int 27 (2007) 329-334
56. Dhiman R.K., Jain S., Maheshwari U., Bhalla A., Sharma N., Ahluwalia J., et al. Early indicators of prognosis in fulminant hepatic failure: an assessment of the Model for End-Stage Liver Disease (MELD) and King's College Hospital criteria. Liver Transpl 13 (2007) 814-821
57. Zhou L., Dong P.-L., and Ding H.-G. Comparison scoring model of severe viral hepatitis and model of end stage liver disease for the prognosis of patients with liver failure in China. World J Gastroenterol 13 (2007) 2999-3002
58. Pelaez-Luna M., Martinez-Salgado J., and Olivera-Martinez M.A. Utility of the Mayo end-stage liver disease score, King's college criteria and a new in-hospital mortality score in the prognosis of in-hospital mortality in acute liver failure. Transpl Proc 38 (2006) 927-929
59. O'Grady J.G., Schalm S.W., and Willliams R. Acute liver failure: redefining the syndromes. Lancet 342 (1993) 273-275
60. Section 121.8, Federal Register, [FR Doc. 98-8191] 42 CFR Part 121 April 2, 1998.